Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604224 | 0.84 | RCE1 (0.63) | AOC2GAACYP2C19MAOBRCE1 | |
| SCHEMBL23370187 | 0.79 | CYP2C19 (0.62) | AOC2GAACYP2C19MAOBRCE1 | |
| SCHEMBL11213086 | 0.79 | CYP2C19 (0.59) | AOC2GAACYP2C19MAOBRCE1 | |
| SCHEMBL23370122 | 0.78 | AOC2 (0.61) | AOC2GAACYP2C19MAOBRCE1 | |
| SCHEMBL23370190 | 0.76 | AOC2 (0.61) | AOC2GAACYP2C19MAOBRCE1 | |
| SCHEMBL23370125 | 0.75 | AOC2 (0.60) | AOC2GAACYP2C19MAOBKMT2A | |
| SCHEMBL23370108 | 0.74 | AOC2 (0.44) | AOC2GAACYP2C19MAOBRCE1 | |
| SCHEMBL9227152 | 0.74 | CYP2C19 (0.47) | AOC2GAACYP2C19MAOBRCE1 | |
| SCHEMBL9293223 | 0.73 | L3MBTL1 (0.65) | KMT2ATSHR | |
| SCHEMBL23358537 | 0.72 | AOC2 (1.00) | AOC2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026801-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210147360-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026801-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | AOC2 39/4885GAA 63/4885CYP2C19 664/4885 |
| US-20210147360-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | AOC2 39/4885GAA 63/4885CYP2C19 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.